Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
October 09, 2020 16:01 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
Retrophin Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
March 09, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...
Retrophin Reports Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX and PROTECT studies of sparsentan enrolling towards topline readouts to support potential NDA and CMA filings Full year 2019 net product sales of $175 million SAN DIEGO, Feb. 24,...
Retrophin to Present at Upcoming Investor Conferences
February 19, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March:...
Retrophin to Report Fourth Quarter and Full Year 2019 Financial Results
February 10, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the...
Retrophin Reports Third Quarter 2019 Financial Results
October 30, 2019 16:01 ET
|
Retrophin, Inc.
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
October 11, 2019 16:05 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of...
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
October 01, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created...